Open Access

Autophagy inhibition contributes to Endostar sensitization in esophageal squamous cell carcinoma

  • Authors:
    • Xinghua Han
    • Zhanggui Wang
    • Bin Hu
    • Jianming Xu
  • View Affiliations

  • Published online on: September 21, 2017     https://doi.org/10.3892/ol.2017.7017
  • Pages: 6604-6610
  • Copyright: © Han et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Endostar is a novel artificially‑synthesized anti‑angiogenesis drug, and has been approved for clinical use. Previous studies have indicated that patients with esophageal cancer could benefit from Endostar combined with chemotherapy or chemoradiotherapy. However, the most advantageous use of this drug remains to be elucidated. The role of autophagy in cancer treatment remains controversial. The results of the present study demonstrated that Endostar promotes autophagy activation, which is regulated via phosphorylation inhibition of the downstream signaling molecules of the vascular endothelial growth factor, AKT serine/threonine kinase and mechanistic target of rapamycin signaling pathways. Furthermore, inhibiting autophagy using the pharmacological inhibitor chloroquine facilitated the antiproliferative effect of Endostar and increased the number of apoptotic cells, compared with Endostar monotherapy. Taken together, the results of the present study suggest that autophagy activation induced by Endostar serves a protective role in human esophageal cancer treatment, and that autophagy inhibition promotes the antiproliferative role of Endostar. Therefore, the combination of Endostar with an autophagy inhibitor may be a novel prospective approach to improving the efficacy of Endostar for the treatment of patients with esophageal cancer.
View Figures
View References

Related Articles

Journal Cover

December-2017
Volume 14 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Han X, Wang Z, Hu B and Xu J: Autophagy inhibition contributes to Endostar sensitization in esophageal squamous cell carcinoma. Oncol Lett 14: 6604-6610, 2017
APA
Han, X., Wang, Z., Hu, B., & Xu, J. (2017). Autophagy inhibition contributes to Endostar sensitization in esophageal squamous cell carcinoma. Oncology Letters, 14, 6604-6610. https://doi.org/10.3892/ol.2017.7017
MLA
Han, X., Wang, Z., Hu, B., Xu, J."Autophagy inhibition contributes to Endostar sensitization in esophageal squamous cell carcinoma". Oncology Letters 14.6 (2017): 6604-6610.
Chicago
Han, X., Wang, Z., Hu, B., Xu, J."Autophagy inhibition contributes to Endostar sensitization in esophageal squamous cell carcinoma". Oncology Letters 14, no. 6 (2017): 6604-6610. https://doi.org/10.3892/ol.2017.7017